Extract

The Childhood Arthritis and Rheumatology Research Alliance (CARRA) is pleased to announce completed enrollment of 403 newly diagnosed children with polyarticular JIA children in STOP-JIA (Start Time Optimization of Biologic Therapy in Polyarticular JIA). “We are excited that we were able to complete enrollment in the largest prospective research study of newly diagnosed JIA patients. CARRA was formed a little over 15 years ago to make it possible to do large-scale studies like this in rare rheumatic diseases like JIA,” said Dr. Yukiko Kimura, the lead investigator of the STOP-JIA study and immediate Past President of CARRA.

What is STOP-JIA about?

JIA is one of the leading causes of acquired disability in children and has no cure. The most common form is polyarticular (poly-JIA), meaning 5 or more joints are involved. Symptoms include pain, fatigue, and stiffness, and it can lead to permanent joint damage and disability.

Over the past 10-20 years, treatment has changed as new medications have become available to treat poly-JIA. The medications have drastically improved outcomes for children. However, little evidence exists to know when to start the new medications. STOP-JIA compares patient outcomes depending on when the new medicines are started. Once the study ends in 2019, the results will indicate which strategy works best.

You do not currently have access to this article.

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.